|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CFD |
Gene summary for CFD |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CFD | Gene ID | 1675 |
| Gene name | complement factor D | |
| Gene Alias | ADIPSIN | |
| Cytomap | 19p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0002252 | UniProtAcc | A6XNE2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1675 | CFD | N_HPV_2 | Human | Cervix | N_HPV | 3.95e-14 | 5.03e-01 | -0.0131 |
| 1675 | CFD | CCII_1 | Human | Cervix | CC | 2.48e-03 | -2.64e-01 | 0.3249 |
| 1675 | CFD | Tumor | Human | Cervix | CC | 1.56e-10 | 3.28e-01 | 0.1241 |
| 1675 | CFD | sample3 | Human | Cervix | CC | 2.42e-25 | 4.92e-01 | 0.1387 |
| 1675 | CFD | H2 | Human | Cervix | HSIL_HPV | 1.21e-11 | 5.42e-01 | 0.0632 |
| 1675 | CFD | T1 | Human | Cervix | CC | 3.36e-03 | -2.41e-01 | 0.0918 |
| 1675 | CFD | T3 | Human | Cervix | CC | 5.10e-25 | 5.30e-01 | 0.1389 |
| 1675 | CFD | LZE2T | Human | Esophagus | ESCC | 8.44e-04 | 2.04e+00 | 0.082 |
| 1675 | CFD | LZE4T | Human | Esophagus | ESCC | 4.26e-04 | 1.81e-01 | 0.0811 |
| 1675 | CFD | LZE5T | Human | Esophagus | ESCC | 6.14e-09 | 9.20e-01 | 0.0514 |
| 1675 | CFD | LZE8T | Human | Esophagus | ESCC | 1.35e-02 | 4.14e-02 | 0.067 |
| 1675 | CFD | LZE22T | Human | Esophagus | ESCC | 3.67e-02 | 3.35e-01 | 0.068 |
| 1675 | CFD | LZE24T | Human | Esophagus | ESCC | 8.12e-17 | 4.43e-01 | 0.0596 |
| 1675 | CFD | P1T-E | Human | Esophagus | ESCC | 6.06e-12 | 5.05e-01 | 0.0875 |
| 1675 | CFD | P2T-E | Human | Esophagus | ESCC | 6.04e-08 | 6.61e-01 | 0.1177 |
| 1675 | CFD | P4T-E | Human | Esophagus | ESCC | 4.91e-17 | 6.48e-01 | 0.1323 |
| 1675 | CFD | P5T-E | Human | Esophagus | ESCC | 2.58e-48 | 1.20e+00 | 0.1327 |
| 1675 | CFD | P8T-E | Human | Esophagus | ESCC | 3.96e-10 | 8.08e-01 | 0.0889 |
| 1675 | CFD | P9T-E | Human | Esophagus | ESCC | 7.27e-19 | 1.60e+00 | 0.1131 |
| 1675 | CFD | P10T-E | Human | Esophagus | ESCC | 1.56e-22 | 1.09e+00 | 0.116 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190199821 | Oral cavity | NEOLP | toxin transport | 10/2005 | 40/18723 | 8.10e-03 | 3.99e-02 | 10 |
| GO:000225313 | Oral cavity | NEOLP | activation of immune response | 55/2005 | 375/18723 | 9.87e-03 | 4.62e-02 | 55 |
| GO:00072195 | Prostate | BPH | Notch signaling pathway | 41/3107 | 172/18723 | 8.95e-03 | 3.83e-02 | 41 |
| GO:000721912 | Prostate | Tumor | Notch signaling pathway | 44/3246 | 172/18723 | 4.02e-03 | 2.04e-02 | 44 |
| GO:003133027 | Skin | AK | negative regulation of cellular catabolic process | 61/1910 | 262/18723 | 4.95e-10 | 5.42e-08 | 61 |
| GO:000989526 | Skin | AK | negative regulation of catabolic process | 68/1910 | 320/18723 | 3.17e-09 | 2.65e-07 | 68 |
| GO:003238619 | Skin | AK | regulation of intracellular transport | 65/1910 | 337/18723 | 3.23e-07 | 1.27e-05 | 65 |
| GO:001063924 | Skin | AK | negative regulation of organelle organization | 64/1910 | 348/18723 | 2.19e-06 | 6.25e-05 | 64 |
| GO:00072198 | Skin | AK | Notch signaling pathway | 34/1910 | 172/18723 | 1.20e-04 | 1.50e-03 | 34 |
| GO:19021157 | Skin | AK | regulation of organelle assembly | 36/1910 | 186/18723 | 1.21e-04 | 1.50e-03 | 36 |
| GO:001050618 | Skin | AK | regulation of autophagy | 51/1910 | 317/18723 | 6.97e-04 | 5.96e-03 | 51 |
| GO:003629325 | Skin | AK | response to decreased oxygen levels | 51/1910 | 322/18723 | 9.99e-04 | 7.88e-03 | 51 |
| GO:000166625 | Skin | AK | response to hypoxia | 49/1910 | 307/18723 | 1.05e-03 | 8.20e-03 | 49 |
| GO:004819319 | Skin | AK | Golgi vesicle transport | 47/1910 | 296/18723 | 1.46e-03 | 1.06e-02 | 47 |
| GO:007048225 | Skin | AK | response to oxygen levels | 53/1910 | 347/18723 | 1.84e-03 | 1.27e-02 | 53 |
| GO:000963626 | Skin | AK | response to toxic substance | 42/1910 | 262/18723 | 2.11e-03 | 1.40e-02 | 42 |
| GO:000689216 | Skin | AK | post-Golgi vesicle-mediated transport | 20/1910 | 104/18723 | 3.91e-03 | 2.30e-02 | 20 |
| GO:00022535 | Skin | AK | activation of immune response | 54/1910 | 375/18723 | 5.90e-03 | 3.20e-02 | 54 |
| GO:001623618 | Skin | AK | macroautophagy | 43/1910 | 291/18723 | 8.39e-03 | 4.16e-02 | 43 |
| GO:000225314 | Skin | SCCIS | activation of immune response | 33/919 | 375/18723 | 8.93e-04 | 1.15e-02 | 33 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa05171110 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
| hsa0517125 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa051504 | Cervix | HSIL_HPV | Staphylococcus aureus infection | 21/459 | 96/8465 | 2.93e-08 | 1.43e-06 | 1.16e-06 | 21 |
| hsa0517135 | Cervix | HSIL_HPV | Coronavirus disease - COVID-19 | 91/459 | 232/8465 | 2.14e-56 | 3.13e-54 | 2.53e-54 | 91 |
| hsa0515011 | Cervix | HSIL_HPV | Staphylococcus aureus infection | 21/459 | 96/8465 | 2.93e-08 | 1.43e-06 | 1.16e-06 | 21 |
| hsa0517145 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa051502 | Cervix | N_HPV | Staphylococcus aureus infection | 15/349 | 96/8465 | 7.81e-06 | 1.01e-04 | 7.90e-05 | 15 |
| hsa0517155 | Cervix | N_HPV | Coronavirus disease - COVID-19 | 47/349 | 232/8465 | 1.79e-20 | 4.86e-18 | 3.80e-18 | 47 |
| hsa051503 | Cervix | N_HPV | Staphylococcus aureus infection | 15/349 | 96/8465 | 7.81e-06 | 1.01e-04 | 7.90e-05 | 15 |
| hsa05171211 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
| hsa05171310 | Esophagus | ESCC | Coronavirus disease - COVID-19 | 156/4205 | 232/8465 | 3.18e-08 | 2.68e-07 | 1.37e-07 | 156 |
| hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
| hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
| hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
| hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
| hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CFD | SNV | Missense_Mutation | c.16C>G | p.Arg6Gly | p.R6G | protein_coding | tolerated(0.32) | benign(0) | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CFD | SNV | Missense_Mutation | novel | c.331C>T | p.Pro111Ser | p.P111S | protein_coding | tolerated(0.19) | probably_damaging(0.956) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CFD | SNV | Missense_Mutation | novel | c.688N>G | p.Thr230Ala | p.T230A | protein_coding | tolerated(0.12) | benign(0.063) | TCGA-AX-A2HJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CFD | SNV | Missense_Mutation | rs757038801 | c.49G>A | p.Ala17Thr | p.A17T | protein_coding | tolerated(0.3) | benign(0) | TCGA-B5-A11Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Hormone Therapy | megace | SD | |
| CFD | SNV | Missense_Mutation | novel | c.701N>A | p.Arg234His | p.R234H | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
| CFD | SNV | Missense_Mutation | novel | c.62N>T | p.Glu21Val | p.E21V | protein_coding | deleterious(0.01) | benign(0) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1675 | CFD | ENZYME, DRUGGABLE GENOME, PROTEASE | antibody | 252166506 | LAMPALIZUMAB | |
| 1675 | CFD | ENZYME, DRUGGABLE GENOME, PROTEASE | Anti-Factor D | |||
| 1675 | CFD | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166508 | ||
| 1675 | CFD | ENZYME, DRUGGABLE GENOME, PROTEASE | ACH-4471 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |